16 results on '"Minucci, Saverio"'
Search Results
2. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
- Author
-
Ablain, Julien, Rice, Kim, Soilihi, Hassane, de Reynies, Aurélien, Minucci, Saverio, and de Thé, Hugues
- Subjects
TREATMENT of acute promyelocytic leukemia ,TUMOR proteins ,RETINOIC acid receptors ,NUCLEAR receptors (Biochemistry) ,CELLULAR signal transduction ,CHIMERIC proteins - Abstract
Acute promyelocytic leukemia (APL) is driven by the promyelocytic leukemia (PML)-retinoic acid receptor-α (PML-RARA) fusion protein, which interferes with nuclear receptor signaling and PML nuclear body (NB) assembly. APL is the only malignancy definitively cured by targeted therapies: retinoic acid (RA) and/or arsenic trioxide, which both trigger PML-RARA degradation through nonoverlapping pathways. Yet, the cellular and molecular determinants of treatment efficacy remain disputed. We demonstrate that a functional Pml-transformation-related protein 53 (Trp53) axis is required to eradicate leukemia-initiating cells in a mouse model of APL. Upon RA-induced PML-RARA degradation, normal Pml elicits NB reformation and induces a Trp53 response exhibiting features of senescence but not apoptosis, ultimately abrogating APL-initiating activity. Apart from triggering PML-RARA degradation, arsenic trioxide also targets normal PML to enhance NB reformation, which may explain its clinical potency, alone or with RA. This Pml-Trp53 checkpoint initiated by therapy-triggered NB restoration is specific for PML-RARA-driven APL, but not the RA-resistant promyelocytic leukemia zinc finger (PLZF)-RARA variant. Yet, as NB biogenesis is druggable, it could be therapeutically exploited in non-APL malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
3. SILAC-based proteomic analysis to dissect the 'histone modification signature' of human breast cancer cells.
- Author
-
Cuomo, Alessandro, Moretti, Simona, Minucci, Saverio, and Bonaldi, Tiziana
- Subjects
PROTEOMICS ,CANCER cells ,BREAST cancer ,POST-translational modification ,HISTONES ,CELL culture ,MASS spectrometry ,CHROMATIN - Abstract
In living cells, the N-terminal tails of core histones, the proteinaceous component of nucleosomes, are subjected to a range of covalent post-translational modifications (PTMs), which have specific roles in modulating chromatin structure and function. A growing body of evidence suggests that deregulation of histone modification patterns, upstream or downstream of DNA methylation, is a critical event in cancer initiation and progression. However, a comprehensive description of how histone modifications, singly or in combination, is disrupted in transformed cells is missing; consequently the issue whether and how specific changes in histone PTMs patterns correlate to particular tumor features is still elusive. In the present study, we focused on human breast cancer and comprehensively analyzed PTMs on histone H3 and H4 from four cancer cell lines (MCF7, MDA-MB231, MDA-MB453 and T-47D), in comparison with normal epithelial breast cells. We performed high-resolution mass spectrometry analysis of histones, in combination with stable isotope labeling with amino acids in cell culture (SILAC), to quantitatively track the modification changes in cancer cells, as compared to their normal counterpart. Our investigation focuses on lysine acetylation and methylation on fourteen distinct sites in H3 and H4. We observed significant changes for several modifications in cancer cells: while in a few cases those modifications had been previously described as a hallmark of human tumors, we could identify novel modifications, whose abundance is significantly altered in breast cancer cells. Overall, these modifications may represent part of a 'breast cancer-specific epigenetic signature', with implications in the characterization of histone-related biomarkers. This work demonstrates that SILAC-based proteomics is a powerful tool to study qualitatively and quantitatively histone PTMs patterns, contributing significantly to the comprehension of epigenetic phenomena in cancer biology. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
4. HDACs link the DNA damage response, processing of double-strand breaks and autophagy.
- Author
-
Robert, Thomas, Vanoli, Fabio, Chiolo, Irene, Shubassi, Ghadeer, Bernstein, Kara A., Rothstein, Rodney, Botrugno, Oronza A., Parazzoli, Dario, Oldani, Amanda, Minucci, Saverio, and Foiani, Marco
- Subjects
BIOCHEMICAL genetics ,ACETYLTRANSFERASES ,IMMUNOSUPPRESSIVE agents ,DNA damage ,GENETIC mutation - Abstract
Protein acetylation is mediated by histone acetyltransferases (HATs) and deacetylases (HDACs), which influence chromatin dynamics, protein turnover and the DNA damage response. ATM and ATR mediate DNA damage checkpoints by sensing double-strand breaks and single-strand-DNA-RFA nucleofilaments, respectively. However, it is unclear how acetylation modulates the DNA damage response. Here we show that HDAC inhibition/ablation specifically counteracts yeast Mec1 (orthologue of human ATR) activation, double-strand-break processing and single-strand-DNA-RFA nucleofilament formation. Moreover, the recombination protein Sae2 (human CtIP) is acetylated and degraded after HDAC inhibition. Two HDACs, Hda1 and Rpd3, and one HAT, Gcn5, have key roles in these processes. We also find that HDAC inhibition triggers Sae2 degradation by promoting autophagy that affects the DNA damage sensitivity of hda1 and rpd3 mutants. Rapamycin, which stimulates autophagy by inhibiting Tor, also causes Sae2 degradation. We propose that Rpd3, Hda1 and Gcn5 control chromosome stability by coordinating the ATR checkpoint and double-strand-break processing with autophagy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.
- Author
-
Di Micco, Raffaella, Sulli, Gabriele, Dobreva, Miryana, Liontos, Michalis, Botrugno, Oronza A., Gargiulo, Gaetano, dal Zuffo, Roberto, Matti, Valentina, d'Ario, Giovanni, Montani, Erica, Mercurio, Ciro, Hahn, William C., Gorgoulis, Vassilis, Minucci, Saverio, and d'Adda di Fagagna, Fabrizio
- Subjects
DNA damage ,HETEROCHROMATIC genes ,AGING ,MOLECULAR biology ,CANCER risk factors ,FIBROBLASTS ,ATAXIA telangiectasia ,DNA replication ,HISTONE deacetylase - Abstract
Two major mechanisms have been causally implicated in the establishment of cellular senescence: the activation of the DNA damage response (DDR) pathway and the formation of senescence-associated heterochromatic foci (SAHF). Here we show that in human fibroblasts resistant to premature p16
INK4a induction, SAHF are preferentially formed following oncogene activation but are not detected during replicative cellular senescence or on exposure to a variety of senescence-inducing stimuli. Oncogene-induced SAHF formation depends on DNA replication and ATR (ataxia telangiectasia and Rad3-related). Inactivation of ATM (ataxia telangiectasia mutated) or p53 allows the proliferation of oncogene-expressing cells that retain increased heterochromatin induction. In human cancers, levels of heterochromatin markers are higher than in normal tissues, and are independent of the proliferative index or stage of the tumours. Pharmacological and genetic perturbation of heterochromatin in oncogene-expressing cells increase DDR signalling and lead to apoptosis. In vivo, a histone deacetylase inhibitor (HDACi) causes heterochromatin relaxation, increased DDR, apoptosis and tumour regression. These results indicate that heterochromatin induced by oncogenic stress restrains DDR and suggest that the use of chromatin-modifying drugs in cancer therapies may benefit from the study of chromatin and DDR status of tumours. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
6. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.
- Author
-
Viale, Andrea, De Franco, Francesca, Orleth, Annette, Cambiaghi, Valeria, Giuliani, Virginia, Bossi, Daniela, Ronchini, Chiara, Ronzoni, Simona, Muradore, Ivan, Monestiroli, Silvia, Gobbi, Alberto, Alcalay, Myriam, Minucci, Saverio, and Pelicci, Pier Giuseppe
- Subjects
LEUKEMIA genetics ,STEM cells ,CELL cycle ,HEMATOPOIETIC stem cells ,ONCOGENES ,GENE expression ,DNA damage ,DNA repair ,PHYSIOLOGY - Abstract
Rare cells with the properties of stem cells are integral to the development and perpetuation of leukaemias. A defining characteristic of stem cells is their capacity to self-renew, which is markedly extended in leukaemia stem cells. The underlying molecular mechanisms, however, are largely unknown. Here we demonstrate that expression of the cell-cycle inhibitor p21 is indispensable for maintaining self-renewal of leukaemia stem cells. Expression of leukaemia-associated oncogenes in mouse haematopoietic stem cells (HSCs) induces DNA damage and activates a p21-dependent cellular response, which leads to reversible cell-cycle arrest and DNA repair. Activated p21 is critical in preventing excess DNA-damage accumulation and functional exhaustion of leukaemic stem cells. These data unravel the oncogenic potential of p21 and suggest that inhibition of DNA repair mechanisms might function as potent strategy for the eradication of the slowly proliferating leukaemia stem cells. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
7. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
- Author
-
Minucci, Saverio and Pelicci, Pier Giuseppe
- Subjects
- *
HISTONE deacetylase , *AMIDASES , *DRUG development , *CANCER treatment , *CLINICAL trials , *CLINICAL medicine research , *CARCINOGENESIS , *MEDICAL protocols - Abstract
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.
- Author
-
Insinga, Alessandra, Monestiroli, Silvia, Ronzoni, Simona, Gelmetti, Vania, Marchesi, Francesco, Viale, Andrea, Altucci, Lucia, Nervi, Clara, Minucci, Saverio, and Pelicci, Pier Giuseppe
- Subjects
CANCER treatment ,APOPTOSIS ,CELL death ,CANCER ,RECEPTOR antibodies ,ENZYME inhibitors - Abstract
Histone deacetylases (HDACs) regulate transcription and specific cellular functions, such as tumor suppression by p53, and are frequently altered in cancer. Inhibitors of HDACs (HDACIs) possess antitumor activity and are well tolerated, supporting the idea that their use might develop as a specific strategy for cancer treatment. The molecular basis for their selective antitumor activity is, however, unknown. We investigated the effects of HDACIs on leukemias expressing the PML-RAR or AML1-ETO oncoproteins, known to initiate leukemogenesis through deregulation of HDACs. Here we report that: (i) HDACIs induce apoptosis of leukemic blasts, although oncogene expression is not sufficient to confer HDACI sensitivity to normal cells; (ii) apoptosis is p53 independent and depends, both in vitro and in vivo, upon activation of the death receptor pathway (TRAIL and Fas signaling pathways); (iii) TRAIL, DR5, FasL and Fas are upregulated by HDACIs in the leukemic cells, but not in normal hematopoietic progenitors. These results show that sensitivity to HDACIs in leukemias is a property of the fully transformed phenotype and depends on activation of a specific death pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis.
- Author
-
Trinei, Mirella, Giorgio, Marco, Cicalese, Angelo, Barozzi, Sara, Ventura, Andrea, Migliaccio, Enrica, Milia, Elisabetta, Padura, Ines Martin, Raker, Veronica A., Maccarana, Marco, Petronilli, Valeria, Minucci, Saverio, Bernardi, Paolo, and Lanfrancone, Luisa
- Subjects
REACTIVE oxygen species ,P53 antioncogene ,APOPTOSIS - Abstract
Presents a study that investigated the molecular mechanisms underlying oxidative stress resistance of the p66Shc. Significance of reactive oxygen species to the theory of aging; Background on p66Shc; Analysis of the role of the p53 tumor suppressor in the regulation of oxidative stress-induced apoptosis.
- Published
- 2002
- Full Text
- View/download PDF
10. PML NBs associate with the HMre11 complex and p53 at sites of irradiation induced DNA damage.
- Author
-
Carbone, Roberta, Pearson, Mark, Minucci, Saverio, and Pelicci, Pier Guiseppe
- Subjects
PROTEINS ,FIBROBLASTS ,IONIZING radiation ,LEUKEMIA - Abstract
Presents a study that examined the modification of promyelocytic leukemia protein nuclear bodies (PML NB) and the recognition of sites of DNA breaks in human fibroblasts after ionizing radiation. Functions of PML NB; Background on PML; Characteristics of acute promyelocytic leukemia; Components of PML NB; Types of damage response pathways.
- Published
- 2002
- Full Text
- View/download PDF
11. Common themes in the pathogenesis of acute myeloid leukemia.
- Author
-
Alcalay, Myriam, Orleth, Annette, Sebastiani, Carla, Meani, Natalia, Chiaradonna, Ferdinando, Casciari, Cristina, Sciurpi, Maria Teresa, Gelmetti, Vania, Riganelli, Daniela, Minucci, Saverio, Fagioli, Marta, and Pelicci, Pier Giuseppe
- Subjects
ACUTE myeloid leukemia ,PROTEINS ,CELLS - Abstract
The pathogenesis of acute myeloid leukemia is associated with the appearance of oncogenic fusion proteins generated as a consequence of specific chromosome translocations. Of the two components of each fusion protein, one is generally a transcription factor, whereas the other partner is more variable in function, but often involved in the control of cell survival and apoptosis. As a consequence, AML-associated fusion proteins function as aberrant transcriptional regulators that interfere with the process of myeloid differentiation, determine a stage-specific arrest of maturation and enhance cell survival in a cell-type specific manner. The abnormal regulation of transcriptional networks occurs through common mechanisms that include recruitment of aberrant co-repressor complexes, alterations in chromatin remodeling, and disruption of specific subnuclear compartments. The identification and analysis of common and specific target genes regulated by AML fusion proteins will be of fundamental importance for the full understanding of acute myeloid leukemogenesis and for the implementation of disease-specific drug design. Oncogene (2001) 20, 5680–5694. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
12. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
- Author
-
Minucci, Saverio, Nervi, Clara, Coco, Francesco Lo, and Pelicci, Pier Giuseppe
- Subjects
- *
HISTONE deacetylase , *MOLECULES , *ACUTE leukemia , *CARCINOGENESIS , *LEUKEMIA treatment - Abstract
Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias. Oncogene (2001) 20, 3110–3115. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
13. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.
- Author
-
Pearson, Mark, Carbone, Roberta, Sebastiani, Carla, Cioce, Mario, Fagioli, Marta, Saito, Shin'ichi, Higashimoto, Yulchiro, Appella, Ettore, Minucci, Saverio, Pandolfi, Pier Paolo, and Pelicci, Pier Giuseppe
- Subjects
TUMOR proteins ,ACETYLATION ,ONCOGENES ,BIOCHEMISTRY ,SCIENTIFIC experimentation - Abstract
Reports that the tumor suppressor PML regulates the p53 response to oncogenic signals. Details regarding protein stability and post-translational modification; Dependence of p53 on PML bodies for acetylation and senescence upon oncogene expression; Details and conclusions of the study.
- Published
- 2000
- Full Text
- View/download PDF
14. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
- Author
-
Grignani, Francesco, De Matteis, Silvia, Nervi, Clara, Tomassoni, Lucia, Gelmetti, Vania, Cioce, Mario, Fanelli, Mirco, Ruthardt, Marthin, Ferrara, Fabiana F., Zamir, Iris, Seiser, Christian, Grignani, Fausto, Lazar, Mitchell A., Minucci, Saverio, and Pelicci, Pier Giuseppe
- Subjects
TRETINOIN ,HISTONES ,LEUKEMIA ,GENETIC repressors ,MOLECULES - Abstract
Presents research which showed that both promyelocytic leukemia-retinoic acid receptor-alpha (PML-RAR-alpha) and promyelocytic leukemia zinc-finger (PLZF-RAR-alpha) fusion proteins recruit the nuclear co-repressor (N-CoR)-histone deacetylase complex. Transforming proteins of acute promyelocytic leukemias (APL); Retinoic acid (RA)-target genes being downstream effectors; Treatment with RA; More.
- Published
- 1998
- Full Text
- View/download PDF
15. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.
- Author
-
Nguyen, Van T. M., Barozzi, Iros, Faronato, Monica, Lombardo, Ylenia, Steel, Jennifer H., Patel, Naina, Darbre, Philippa, Castellano, Leandro, Győrffy, Balázs, Woodley, Laura, Meira, Alba, Patten, Darren K., Vircillo, Valentina, Periyasamy, Manikandan, Ali, Simak, Frige, Gianmaria, Minucci, Saverio, Coombes, R. Charles, and Magnani, Luca
- Published
- 2015
- Full Text
- View/download PDF
16. Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.
- Author
-
Elgendy, Mohamed, Ciro, Marco, Abdel-Aziz, Amal Kamal, Belmonte, Giuseppe, Zuffo, Roberto Dal, Mercurio, Ciro, Miracco, Clelia, Lanfrancone, Luisa, Foiani, Marco, and Minucci, Saverio
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.